Skip to main content

Table 1 Local blood flow in the examined tissues under resting condition before endothelin-1 administration in normal and STZ-diabetic rats

From: Endothelin-induced changes in blood flow in STZ-diabetic and non-diabetic rats: relation to nitric oxide synthase and cyclooxygenase inhibition

Tissue (unit)

Type of rat

Blood flow

No pretreatment

normal (n = 7),

STZ (n = 5)

Blood flow

L-NAME pretreated

normal (n = 8),

STZ (n = 6)

Blood flow

indomethacin pretreated

normal (n = 5),

STZ (n = 5)

Right kidney [g/min/g(tw)]

Normal

5.8 ± 0.3*

2.3 ± 0.3

6.1 ± 0.3

STZ

4.0 ± 0.4

2.7 ± 0.1

3.3 ± 0.4

Left kidney [g/min/g(tw)]

Normal

5.7 ± 0.3*

2.3 ± 0.2

5.7 ± 0.3

STZ

3.9 ± 0.4

2.5 ± 0.1

3.1 ± 0.5

Heart [g/min/g(tw)]

Normal

4.2 ± 0.4

2.8 ± 0.2*

4.8 ± 0.5

STZ

3.6 ± 0.4

2.2 ± 0.1

3.6 ± 0.4

Skeletal muscle [g/min/g(tw)]

Normal

0.16 ± 0.03

0.06 ± 0.01*

0.13 ± 0.04

STZ

0.15 ± 0.03

0.12 ± 0.02

0.13 ± 0.05

Choroid (mg/min)

Normal

59 ± 14

6 ± 2

47 ± 15

STZ

45 ± 6

10 ± 3

52 ± 12

Anterior uvea (mg/min)

Normal

49 ± 6

16 ± 2

48 ± 7

STZ

38 ± 2

18 ± 2

41 ± 6

Retina (mg/min)

Normal

2 ± 1

2 ± 1

3 ± 1

STZ

4 ± 1

2 ± 1

1 ± 1

Brain (left hemisphere) [g/min/g(tw)]

Normal

0.84 ± 0.07

  

STZ

0.80 ± 0.07

  
  1. Data are the mean ± SEM. Mann–Whitney U test between groups
  2. STZ Streptozotocin, L-NAME a NO synthase inhibitor, Indomethacin a cyclooxygenase inhibitor
  3. * P < 0.05